Last month, the Lymphoma Hub reported on a hold, put in place by the U.S. Food and Drug Administration (FDA), on clinical trials of the experimental drug selinexor (KPT-330) in CLL and DLBCL.
On 30th March 2017, the FDA’s Division of Hematology Products lifted the clinical hold. Enrollment and dosing of new patients is set to resume in all trials of selinexor in hematological malignancies.
1. Seeking Alpha. FDA lifts partial clinical hold on clinical studies of Karyopharm's selinexor. 2017 Mar 30. https://seekingalpha.com/news/3254399-fda-lifts-partial-clinical-hold-clinical-studies-karyopharms-selinexor. [Accessed 2017 Apr 06].